Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00706134
Other study ID # CSPP100A2405
Secondary ID
Status Completed
Phase Phase 3
First received June 25, 2008
Last updated June 24, 2011
Start date May 2008
Est. completion date April 2009

Study information

Verified date June 2011
Source Novartis
Contact n/a
Is FDA regulated No
Health authority Czech Republic: State Institute for Drug ControlFrance: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)Germany: Federal Institute for Drugs and Medical DevicesItaly: National Institute of HealthNetherlands: Medicines Evaluation Board (MEB)Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal ProductsSlovakia: State Institute for Drug Control
Study type Interventional

Clinical Trial Summary

This study will evaluate the efficacy and safety of aliskiren 75 mg, 150 mg, and 300 mg in elderly patients with essential hypertension when given with a light meal.


Recruitment information / eligibility

Status Completed
Enrollment 756
Est. completion date April 2009
Est. primary completion date April 2009
Accepts healthy volunteers No
Gender Both
Age group 65 Years and older
Eligibility Inclusion Criteria:

- Male and female outpatients 65 years of age and older.

- Patients who are eligible and able to participate in the study, and who consent to do so after the purpose and nature of the investigation has been clearly explained to them (written informed consent).

- At the randomization visit patients must have an office msSBP greater than or equal to 150 mmHg and < 180 mmHg (msDBP <110 mmHg) with a less than or equal to 15 mmHg difference during the last two visits of the single blind run-in period.

Exclusion Criteria:

- Severe hypertension [Office msDBP =110 mmHg and/or mean sitting systolic blood pressure (msSBP) = 180 mmHg].

- History or evidence of a secondary form of hypertension.

- Known Keith-Wagener grade III or IV hypertensive retinopathy.

- History of hypertensive encephalopathy or cerebrovascular accident, including a history of transient ischemic cerebral attack (TIA).

- Current diagnosis of heart failure (NYHA Class II-IV).

- History of myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention (PCI).

- Current angina pectoris requiring pharmacological therapy other than nitrates.

Other protocol-defined inclusion/exclusion criteria applied to the study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Placebo
Placebo tablet taken once daily in the morning with a light meal.
Aliskiren 75 mg
Aliskiren 75 mg tablet taken once daily in the morning with a light meal.
Aliskiren 150 mg
Aliskiren 150 mg tablet taken once daily in the morning with a light meal.
Aliskiren 300 mg
Aliskiren 300 mg tablet taken once daily in the morning with a light meal.

Locations

Country Name City State
Argentina Investigative Site Buenos Aires
Czech Republic Investigative Site Prague
Germany Investigative Site Berlin
Iceland Investigative Site Reykjavik
Italy Investigative Site Rome
Netherlands Investigative Site Amsterdam
Poland Investigative Site Warsaw
Slovakia Investigative Site Bratislava

Sponsors (1)

Lead Sponsor Collaborator
Novartis

Countries where clinical trial is conducted

Argentina,  Czech Republic,  Germany,  Iceland,  Italy,  Netherlands,  Poland,  Slovakia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Mean Sitting Systolic Blood Pressure (msSBP)From Baseline to End of Study (Week 8) Baseline to end of study (Week 8) No
Secondary Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8) Baseline to end of study (Week 8) No
Secondary Percentage of Patients Achieving Systolic Blood Pressure Response Patients achieving a systolic blood pressure response had to have a msSBP < 140 mmHg at the end of the study and/or a = 20 mmHg reduction in msSBP from baseline to the end of the study. Baseline to end of study (Week 8) No
Secondary Change in Mean 24 Hour Ambulatory Systolic and Diastolic Blood Pressure From Baseline to End of Study Two 24-hour ambulatory blood pressure monitoring (ABPM) evaluations were performed, one at baseline and one at the end of the study. For each evaluation, the ABPM device was attached to the non-dominant arm of the patient. Baseline to end of study (Week 8) No
Secondary Change in the Smoothness Index (SI) of the Ambulatory Systolic Blood Pressure From Baseline to End of Study (Week 8) Smoothness index (SI) is a measure of consistency of the BP reduction over 24 hours. The SI was obtained by first calculating the mean blood pressure value at each hour of the 24-hour ambulatory blood pressure monitoring period, both before and during treatment. Similarly, the change from baseline in blood pressure was calculated at each hour. The average hourly change from baseline (dh) and standard deviation (std dh) of the hourly changes were computed, and the SI was derived: SI = dh/std dh. A negative change score indicates improvement. Baseline to end of study (Week 8) No
Secondary Change in Morning Surge of Ambulatory Systolic Blood Pressure From Baseline to End of Study (Week 8) The morning surge was defined as the average of the hourly means in the last three hours (hours 22, 23, 24) of the 24 hour ambulatory blood pressure monitoring assessment period. Baseline to end of study (week 8) No
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A